# Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Source: https://onco.cc/trials/nct05775159/  
OnCo record `nct05775159` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Bevacizumab, Lenvatinib, Rilvegostomig in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer is a phase 2 interventional study registered as NCT05775159 by AstraZeneca, with 294 participants planned, started 2023-04-24 and due to reach its primary completion in 2026-10-27. Interventions recorded: Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05775159
- Phase: 2
- Setting: A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
- Sponsor: AstraZeneca
- Enrolled: 294

## Sources

- ClinicalTrials.gov NCT05775159: https://clinicaltrials.gov/study/NCT05775159

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05775159.json